Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

Survival following anthracycline-based chemotherapy remains poor among patients with most T-cell lymphoproliferative disorders. This may be attributed, at least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in these lymphomas, including the loss of important tumor suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Murga-Zamalloa, Carlos, Polk, Avery, Hanel, Walter, Chowdhury, Pinki, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Wang, Tianjiao, Phillips, Tycel, Devata, Sumana, Poonnen, Pradeep, Gomez-Gelvez, Juan, Inamdar, Kedar V., Wilcox, Ryan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777707/
https://www.ncbi.nlm.nih.gov/pubmed/29383095
http://dx.doi.org/10.18632/oncotarget.22967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777707/
https://www.ncbi.nlm.nih.gov/pubmed/29383095
http://dx.doi.org/10.18632/oncotarget.22967

Ejemplares similares